Pricing Log in Create free account
Saturday 17 October 2026 Export NAGE’s income statement to Excel — free account

Niagen Bioscience, Inc.

NAGE Healthcare Biotechnology

Niagen Bioscience, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $129.4 million, up 29.9% from fiscal 2024. In the quarter to June 2026, revenue fell 4.28%, EPS fell 80.0% and free cash flow grew 140.6%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.

2.49 0.09 −3.49%
Market cap
$204.2M
P/E
12.5×
Fwd P/E
15.0×
Dividend yield
—
F-score
6/9
Altman Z
10.54
Beneish M
−1.55
Dividend safety
n/a
Overview Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.05
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy 1 — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 34.49%

Capital & Financial Ratios $m

Market Cap 204.15
Revenue 129.08
Net Income 15.99
Free Cash Flow 11.47
Net Debt (66.74)
Current Ratio 6.50 (at or above 1.5: strong)
Debt/Equity 0.00 (at or below 0.5: strong)
P/E ratio 12.45
Fwd P/E 15.00
P/S ratio 1.53
P/B ratio 2.39
Past 5Y EPS Growth —
This Y EPS Growth (35.40%) (below 0%: weak)
Next Y EPS Growth (4.83%) (below 0%: weak)
Next Y revenue growth 2.92%
Next 5Y EPS Growth (2.27%) (below 0%: weak)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 1.0×, against a ten-year median of 4.9×; over the ten years it ranged from 0.9× in 2023 to 19.9× in 2017.
P/S against its own 10 years 9.84%
10-year low 10-year high
P/B against its own 10 years 0.04%
10-year low 10-year high
EV/Sales against its own 10 years 3.24%
10-year low 10-year high
EV/FCF against its own 10 years 0.48%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2023 Powerpack
2022 Powerpack
2021 Powerpack
2020 Powerpack
2019 Powerpack
2017 Powerpack
special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 27 45 65 67
Receivables 5 8 10 9
Inventory 15 9 20 21
Other — — 1 —
50 64 97 98
2023 2024 2025 Q'26
Payables 10 9 11 9
ST’ Debt — — — —
Other 0 1 0 0
21 18 20 15

Compound Annual Growth %

10y 5y 3y
Sales 21.89% 16.91% 21.56%
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 30.67% 36.04% 38.72%

Revenue $m

Mar Jun Sep Dec Year
’26 31 30 — — —
’25 30 31 34 34 129
’24 22 23 26 29 100
’23 23 20 19 21 84
’22 17 17 17 21 72
’21 15 18 17 18 67
’20 14 15 14 15 59
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (1) 3 — — —
’25 8 1 4 1 14
’24 0 0 3 9 12
’23 3 3 0 1 7
’22 (7) (4) (4) 0 (15)
’21 (5) (8) (6) (5) (24)
’20 (5) (2) (4) 0 (11)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 5 3 — — —
’25 8 1 4 1 13
’24 0 0 3 9 12
’23 3 3 0 1 7
’22 (7) (4) (4) 0 (15)
’21 (5) (8) (6) (5) (25)
’20 (5) (2) (4) 0 (11)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 0.07 0.01 — — —
’25 0.06 0.04 0.05 0.05 0.20
’24 (0.01) 0.00 0.02 0.09 0.11
’23 (0.03) (0.03) (0.01) 0.00 (0.07)
’22 (0.11) (0.09) (0.01) (0.02) (0.24)
’21 (0.12) (0.08) (0.13) (0.08) (0.40)
’20 (0.10) (0.06) (0.07) (0.10) (0.33)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low 2.25 2.26 2.79 2.68 2.50 3.70 1.15 1.25 1.36 5.16

Analyst estimates 2026–2028

Powerpack
High 6.18 7.24 6.63 4.95 6.00 23.66 4.03 2.24 7.97 14.69
People
People Employees 93 74 100 110 110 115 113 106 104 117
Revenue/emp, $m 0.23 0.29 0.32 0.42 0.54 0.59 0.64 0.79 0.96 1.11
Income, $m
Income, $m Revenue 22 21 32 46 59 67 72 84 100 129
Gross margin, % 47.96 49.42 50.88 55.67 59.53 61.51 59.40 60.76 61.84 64.28
EBT (4) (17) (33) (32) (20) (27) (17) (5) 9 18
EBT margin, % (16.39) (77.97) (105.57) (69.45) (33.62) (40.22) (22.96) (5.91) 8.89 14.06
Net income (3) (11) (33) (32) (20) (27) (17) (5) 9 17
Depreciation 0 1 1 2 1 1 1 1 1 1
Per share, $
Per share, $ Revenue 0.58 0.48 0.57 0.81 0.97 1.00 1.03 1.11 1.31 1.63
Earnings (0.08) (0.26) (0.61) (0.56) (0.33) (0.40) (0.24) (0.07) 0.11 0.22
Cash flow (0.08) (0.22) (0.38) (0.36) (0.17) (0.36) (0.22) 0.09 0.16 0.17
Capex (0.05) 0.10 (0.03) 0.00 0.00 (0.01) 0.00 0.00 0.00 0.00
Free cash flow (0.12) (0.12) (0.41) (0.36) (0.18) (0.37) (0.22) 0.09 0.16 0.17
Book value 0.27 1.21 0.49 0.36 0.27 0.47 0.41 0.38 0.61 0.97
Shares, m 37 45 55 57 61 67 70 75 76 79
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 51.40 27.65
P/S 5.94 13.36 5.98 5.31 4.95 3.73 1.64 1.28 4.05 3.89
P/B 12.90 5.26 6.94 12.03 17.85 7.92 4.11 3.77 8.75 6.58
EV/Sales 5.97 11.32 5.33 4.95 4.70 3.40 1.38 0.98 3.62 3.40
EV/FCF (27.72) (46.13) (7.52) (11.09) (25.91) (9.32) (6.43) 11.76 30.16 33.40
Cash, $m
Cash, $m Operating cash flow (3) (10) (21) (20) (11) (24) (15) 7 12 14
Capex (2) 5 (1) 0 0 0 0 0 0 0
Free cash flow (5) (5) (22) (21) (11) (25) (15) 7 12 13
Balance, $m
Balance, $m Working capital 7 49 22 18 16 31 29 29 46 77
Total debt 0 0 0 0 0 4 0 0 — —
Net debt (1) (45) (22) (19) (17) (24) (20) (27) (45) (65)
Shareholders’ equity 10 54 27 20 16 32 29 28 46 77
Returns, %
Returns, % ROA (15.21) (27.59) (63.49) (77.95) (50.70) (56.40) (29.56) (9.06) 13.88 19.90
ROIC (20.93) (116.91) (441.21) (1,184.89) 0.00 (220.84) (141.07) (306.16) 336.73 86.63
ROE (38.40) (35.66) (82.25) (135.01) (108.09) (112.68) (54.77) (17.29) 22.94 28.35
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Niagen Bioscience, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
IFRX InflaRx N.V. $212.2M — (loss-making) — (loss-making) −128.93% (below 0%: shrinking) n/m +69.33% (above 0%: growing) 14,029.95% 0.00% Compare
ZNTL Zentalis Pharmaceuticals, Inc. $212.1M — (loss-making) — (loss-making) — n/m −9.06% (below 0%: shrinking) 100.00% 0.00% Compare
LRMR Larimar Therapeutics, Inc. $206.7M — (loss-making) — — n/m −127.63% (below 0%: shrinking) 0.00% 0.00% Compare
PRQR ProQR Therapeutics N.V. $204.6M — (loss-making) — (loss-making) +135.03% (above 0%: growing) n/m −1.06% (below 0%: shrinking) 100.00% (100.72%) Compare
NAGE Niagen Bioscience, Inc. $204.2M 12.5× 15.0× −4.28% (below 0%: shrinking) −80.00% (below 0%: shrinking) +140.63% (above 0%: growing) 64.84% 2.35%
LYEL Lyell Immunopharma, Inc. $200.7M — (loss-making) — (loss-making) −50.00% (below 0%: shrinking) n/m +1.31% (above 0%: growing) 100.00% (1,183,425.00%) Compare
RNAC Cartesian Therapeutics, Inc. $199.1M — (loss-making) — (loss-making) −92.91% (below 0%: shrinking) −7.84% (below 0%: shrinking) −6.15% (below 0%: shrinking) 100.00% 0.00% Compare
IVVD Invivyd, Inc. $197.1M — (loss-making) — (loss-making) +21.20% (above 0%: growing) n/m −226.89% (below 0%: shrinking) 91.09% (320.76%) Compare
CGEN Compugen Ltd. $197.0M 5.2× — (loss-making) +107.00% (above 0%: growing) n/m −155.42% (below 0%: shrinking) (3.54%) (339.62%) Compare
Median of peers $202.7M — — −14.40% — −7.60% 100.00% (50.36%)

All 614 Biotechnology stocks →

Niagen Bioscience, Inc. (NAGE) key facts

  • Strength: Niagen Bioscience, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $129.4 million, up 29.9% from fiscal 2024.
  • Niagen Bioscience, Inc. (NAGE) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, NAGE traded at $2.49, a market capitalization of $204.2 million.
  • Return on equity was 28.4% and debt-to-equity 0.00.
  • Its Piotroski F-score is 6 out of 9 and its Altman Z-score is 10.54 (safe zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

Niagen Bioscience, Inc. (NAGE) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/NAGE · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com